Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Diet, Microbiota, and Emerging Therapies in Gastroenterology
This week's episode explores the latest in gastroenterology research, including dietary impacts on IBD, gut microbiota's role in disease, and emerging therapies for ulcerative colitis and Crohn's disease.
Bibliography
1. Diet, Food, and Nutritional Exposures and Inflammatory Bowel Disease or Progression of Disease: an Umbrella Review.
Authors: Christensen C, Knudsen A, Arnesen EK, et al.
Journal: Advances in nutrition (Bethesda, Md.), 2024 May
PMID: 38599319
DOI: 10.1016/j.advnut.2024.100219
2. Lactate and lactylation in sepsis: regulation of immune-metabolic crosstalk and organ injury.
Authors: Li Z, Gu WJ, Li T, et al.
Journal: Frontiers in immunology, 2026
PMID: 42592257
DOI: 10.3389/fimmu.2026.1900179
3. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
Authors: Singh S, Loftus EV Jr, Limketkai BN, et al.
Journal: Gastroenterology, 2024 Dec
PMID: 39572132
DOI: 10.1053/j.gastro.2024.10.001
4. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years.
Authors: Gordon M, de Geus A, Boruta M, et al.
Journal: Journal of pediatric gastroenterology and nutrition, 2026 Aug
PMID: 42159193
DOI: 10.1002/jpn3.70447
5. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
6. Identification of a Druggable Target That Predicts Postoperative Crohn's Disease Recurrence.
Authors: Verstockt S, Schwärzler J, Willeit P, et al.
Journal: Gastroenterology, 2026 Aug
PMID: 41850538
DOI: 10.1053/j.gastro.2026.02.035
7. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Authors: Kopetz S, Yoshino T, Van Cutsem E, et al.
Journal: Nature medicine, 2025 Mar
PMID: 39863775
DOI: 10.1038/s41591-024-03443-3
8. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia.
Authors: Ford AC, Moayyedi P, Black CJ, et al.
Journal: Alimentary pharmacology & therapeutics, 2021 Jan
PMID: 32936964
DOI: 10.1111/apt.16072
9. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
10. Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.
Authors: Paul JK, Azmal M, Haque ASNB, et al.
Journal: World journal of gastroenterology, 2025 Feb 7
PMID: 39926224
DOI: 10.3748/wjg.v31.i5.99913
Authors: Christensen C, Knudsen A, Arnesen EK, et al.
Journal: Advances in nutrition (Bethesda, Md.), 2024 May
PMID: 38599319
DOI: 10.1016/j.advnut.2024.100219
2. Lactate and lactylation in sepsis: regulation of immune-metabolic crosstalk and organ injury.
Authors: Li Z, Gu WJ, Li T, et al.
Journal: Frontiers in immunology, 2026
PMID: 42592257
DOI: 10.3389/fimmu.2026.1900179
3. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
Authors: Singh S, Loftus EV Jr, Limketkai BN, et al.
Journal: Gastroenterology, 2024 Dec
PMID: 39572132
DOI: 10.1053/j.gastro.2024.10.001
4. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years.
Authors: Gordon M, de Geus A, Boruta M, et al.
Journal: Journal of pediatric gastroenterology and nutrition, 2026 Aug
PMID: 42159193
DOI: 10.1002/jpn3.70447
5. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
6. Identification of a Druggable Target That Predicts Postoperative Crohn's Disease Recurrence.
Authors: Verstockt S, Schwärzler J, Willeit P, et al.
Journal: Gastroenterology, 2026 Aug
PMID: 41850538
DOI: 10.1053/j.gastro.2026.02.035
7. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Authors: Kopetz S, Yoshino T, Van Cutsem E, et al.
Journal: Nature medicine, 2025 Mar
PMID: 39863775
DOI: 10.1038/s41591-024-03443-3
8. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia.
Authors: Ford AC, Moayyedi P, Black CJ, et al.
Journal: Alimentary pharmacology & therapeutics, 2021 Jan
PMID: 32936964
DOI: 10.1111/apt.16072
9. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
10. Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.
Authors: Paul JK, Azmal M, Haque ASNB, et al.
Journal: World journal of gastroenterology, 2025 Feb 7
PMID: 39926224
DOI: 10.3748/wjg.v31.i5.99913
